beta

AGLE

Aeglea Biotherapeutics, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Market Cap: 137 Million

Primary Exchange: NASDAQ

Website: http://www.aegleabio.com

Shares Outstanding: 29.1 Million

Float: 25.2 Million

Dividend: (%)

Beta: 1.56209869536

Sector: Health Technology

Industry: Pharmaceuticals: Major

Ethical Flags

Longest drawdown: 1530 trading days

From: 2016-04-08 To: 2020-03-27

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud